Antonio Lee, Ph.D., CEO 

Oct. 13 | 9:45am | Oxford Biomedica Ballroom 

Vienna, VA 


In-person Presentation 

MEDIPOST is a Korean-based company founded in 2000 which became a publicly traded company in 2005, listed on KOSDAQ with a $350 million market cap and 300 employees. The U.S. subsidiary is located in Virginia. MEDIPOST operates the largest private cord blood bank, CELLTREE®, in South Korea with over 280,000 units of private cord blood bank under storage. Each year, over 20,000 private cord blood units are collected and stored at CELLTREE®. MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human Umbilical Cord Blood-derived Mesenchymal Stromal Cells (hUCB-MSCs) with clinical-stage assets in the disease areas of osteoarthritis (OA), broncho-pulmonary dysplasia (BPD), and Alzheimer’s disease (AD). The company’s preclinical-stage pipeline includes Acute Respiratory Distress Syndrome (ARDS), alopecia, and diabetic nephropathy. In addition, MEDIPOST is exploring commercialization of an allogeneic umbilical cord blood-derived regulatory T cell therapeutics pipeline for unmet medical needs, through its subsidiary IMMUNIQUE Therapeutics. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions